NCT06287749 French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
| NCT ID | NCT06287749 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Montpellier |
| Condition | Pancreatic Cancer Resectable |
| Study Type | OBSERVATIONAL |
| Enrollment | 37 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2028-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 37 participants in total. It began in 2024-03-01 with a primary completion date of 2028-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after 1. curative-intended surgery and 2. adjuvant chemotherapy. FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project
Eligibility Criteria
Inclusion Criteria: * Pancreatic ductal adenocarcinoma, according to the assessment of the MDT. * Age 18 years or older. * Scheduled for curative intent surgical resection. Exclusion Criteria: * Hereditary pancreatic cancer. * Verified distant metastases. * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study. * Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening. * Pregnant or nursing woman, or in childbearing age and not willing to use contraception * Adult subject to a legal protection * Not covered by Health insurance * Patient unable to understand and sign written informed consent.
Contact & Investigator
Thomas BARDOL, M.D.
PRINCIPAL INVESTIGATOR
University Hospital, Montpellier
Frequently Asked Questions
Who can join the NCT06287749 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer Resectable. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06287749 currently recruiting?
Yes, NCT06287749 is actively recruiting participants. Contact the research team at c-panabieres@chu-montpellier.fr for enrollment information.
Where is the NCT06287749 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT06287749 clinical trial?
NCT06287749 is sponsored by University Hospital, Montpellier. The principal investigator is Thomas BARDOL, M.D. at University Hospital, Montpellier. The trial plans to enroll 37 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.